M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis

British Journal of Haematology

Volumn 139, Issue 2, 2007, Pages 194-205

  Riccioni, Roberta ^a   Senese, Mara ^a   Diverio, Daniela ^b   Riti, Viviana ^a   Buffolino, Sonia ^b   Mariani, Gualtiero ^a   Boe, Alessandra ^a   Cedrone, Michele ^c   Lo Coco, Francesco ^d   Foà, Robin ^b   Peschle, Cesare ^a   Testa, Ugo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Apoptosis; Leukaemia; Proteasome

Indexed keywords

ALDEHYDE DEHYDROGENASE; BORTEZOMIB; CASPASE 3; CASPASE 8; TUMOR NECROSIS FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL KILLING; CHEMICAL ANALYSIS; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; PRIORITY JOURNAL; STEM CELL;

ALDEHYDE DEHYDROGENASE; APOPTOSIS; BORONIC ACIDS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 8; CELLS, CULTURED; FAS-ASSOCIATED DEATH DOMAIN PROTEIN; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; PROTEASE INHIBITORS; PYRAZINES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STEM CELLS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34848866258     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06757.x     Document Type: Article

References (37)

1. Adams, J. (2004a) The development of proteasome inhibitors in anticancer drugs. Cancer Cell, 5, 417 421.
2. Adams, J. (2004b) The proteasome: a suitable antineoplastic target. Nature Review Cancer, 4, 349 360.
3. Attar, E.C., Angelo, D.J., Sirulnik, A., Wadleigh, M., Ballen, K.K. Miller, K.B. (2005) Addition of bortezomib (Velcade) to AML induction chemotherapy is well tolerated and results in a high complete remission rate. Blood, 106, 2782, (abstract).
4. Bonnet, D. Dick, J.E. (1997) Human acute myeloid leukaemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine, 3, 730 737.
5. Conticello, C., Adamo, L., Giuffrida, R., Vicari, L., Zeuner, A., Eramo, A., Anastasi, G., Memeo, L., Giuffrida, D., Gulisano, M. De Maria, R. (2007) Proteasome inhibitors synergize with TRAIL to induce anaplastic thyroid carcinoma cell death. Journal of Endocrinology and Metababolism, 92, 1938 1942.
6. Cortes, J., Thomas, D., Koller, C., Gilles, F., Estey, E., Faderl, S., Garcia-Manero, G., McConkey, D., Ruiz, S.L., Guerciolini, R., Wright, J. Kantarjian, H. (2004) Phase I study of bortezomib in refractory or relapsed acute leukemias. Clinical Cancer Research, 10, 3371 3376.
7. Deschler, B. Lubbert, M. (2006) Acute myeloid leukaemia: epidemiology and etiology. Cancer, 107, 2099 2107.
8. Dommange, F., Cartron, G., Espanel, C., Gallay, N., Domenech, J., Benboubker, L., Ohresser, M., Colombat, P., Binet, C., Watier, H., Herault, O. GOELAMS Study Group. (2006) CXCL 12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukaemia. FASEB Journal, 20, 1913 1915.
9. Fukazawa, T., Fujiwara, T., Uno, F., Teraishi, F., Kadowaki, Y., Itoshima, T., Takata, Y., Kagawa, S., Roth, J.A., Tschopp, J. Tanaka, M. (2001) Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene, 20, 5225 5231.
10. Guzman, M.L., Swiderski, C.F., Howard, D.S., Grimes, B.A., Rossi, R.M., Szilavassy, S.J. Jordan, C.T. (2002) Preferential apoptosis for primary human leukemic stem cells. Proceedings of the National Academy of Scencesi United States of America, 99, 16220 16225.
11. Hess, D.A., Meyerrose, T.E., Wirthin, L., Craft, T.P., Herrbrich, P.E., Creer, M.H. Nolta, J.A. (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated based on aldehyde dehydrogenase activity. Blood, 104, 1648 1655.
12. Kabore, A.F., Sun, J., Hu, X., McCrea, K., Johnston, J.B. Gibson, S.B. (2006) The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukaemia cells. Apoptosis, 11, 1175 1193.
13. Kim, Y., Suh, N., Sporn, M. Reed, J.C. (2002) An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. Journal of Biological Chemistry, 277, 22320 22329.
14. Konoplev, S., Rassidakis, G.Z., Estey, E., Kantarjian, H., Liakou, C.I., Huang, X., Xiao, L., Andreeff, M., Konopleva, M. Medeiros, L.J. (2007) Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukaemia with normal karyotype. Cancer, 109, 1152 1156.
15. Koschny, R., Holland, H., Sykora, J., Haas, T.L., Sprick, M.R., Ganten, T.M., Krupp, W., Bauer, M., Ahnert, P., Meixensberger, J. Walczak, H. (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clinical Cancer Research, 13, 3403 3412.
16. Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, S.E., Belton, A.A., Walker, H., Whealtley, K., Bowen, D.T., Burnett, A.K., Goldstone, A.H. Linch, D.C. (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukaemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood, 98, 1752 1759.
17. Kraus, M., Ruckrich, T., Reich, M., Gogel, J., Beck, A., Kammer, W., Berkers, C.R., Burg, D., Overkleeft, H., Ovaa, H. Driessen, C. (2007) Activity pattern of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukaemia cells. Leukemia, 21, 84 92.
18. Kumatori, A., Tanaka, K., Inamura, N., Sone, S. Ogura, T. (1990) Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences United States of America, 87, 7071 7075.
19. Liu, X., Yue, P., Chen, S., Hu, L., Lonial, S., Khuri, F.R. Sun, S.Y. (2007) The proteasome inhibitor PS-341 (Bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and surviving expression in human NSCL cells. Cancer Research, 67, 4981 4988.
20. Mani, A. Gelmann, E.P. (2005) The ubiquitin-proteasome pathway and its role in cancer. Journal of Clinical Oncolology, 23, 4776 4789.
21. Meshinchi, S., Woods, W.G. Stirewalt, D.L. (2001) Prevalence and prognostic significance of Flt3 tandem duplication in pediatric acute myeloid leukaemia. Blood, 97, 89 94.
22. Miller, C.P., Ban, K., Dujka, M.E., McConkey, D.J., Munsell, M., Palladino, M. Chandra, J. (2007) NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 110, 267 277.
23. Minderman, H., Zhou, Y., O'Ioughlin, K.L. Baer, M.R. (2007) Bortezomib activity and in vitro interactions with anthracyclines and cytobarine in acute myeloid leukaemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemotherapy Pharmacology, 60, 245 255.
24. Mohle, R., Schittenhelem, M., Fallenschmid, C., Bautz, R.F., Kratz-Albers, K., Serve, H., Brugger, W. Kanz, L. (2000) Functional response of leukemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukemia. British Journal of Haematology, 110, 563 572.
25. Nencioni, A., Grunebach, F., Patrone, F., Ballestrero, A. Brossart, P. (2007) Proteasome inhibitors: antitumor effects and beyond. Leukemia, 21, 30 36.
26. Orlowski, R.Z., Stinchome, T.E., Mitchell, B.S., Shea, T.C., Baldwin, A.S., Stahl, S., Adams, J., Esseltine, D.L., Elliott, P.J., Pien, C.S., Guerciolini, R., Anderson, J.K., Depcick-Smith, N.D., Bhagat, R., Lehman, M.J., Novick, S.C., O'Connor, O.A. Soignet, S.L. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology, 20, 4420 4427.
27. Orlowski, R.Z., Voorhees, P.M., Garcia, R.A., Hall, M.D., Kudrik, F.J., Allred, T., Johri, A.R., Jones, P.E., Ivanova, A., VanDreventer, H.W., Gabriel, D.A., Schea, T.C., Mitchell, B.S., Adams, J., Esseltine, D.L., Trehu, E.G., Green, M., Lehman, M.J., Natoli, S., Collins, J.M., Lindley, C.M. Dees, E.C. (2005) Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood, 105, 3058 3065.
28. Pearce, D.J., Taussig, D., Simpson, C., Allen, K., Rohatiner, A., Lister, T.A. Bonnet, D. (2005) Characterization of cells with a high aldheyde dehydrogenase activity from cord blood and acute myeloid leukaemia samples. Stem Cells, 23, 752 760.
29. Pigneux, A., Mahon, F.X., Moreau-Gaudry, F., Uhalde, M., Verneuil, H.D., Lacombe, F., Reiffers, J., Milpied, N., Praloran, V. Belloc, F. (2007) Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins. Cancer Biology & Therapy, in press.
30. Riccioni, R., Diverio, D., Mariani, G., Buffolino, S., Riti, V., Saulle, E., Petrucci, E., Cedrone, M., Lo-Coco, F., Foà, R., Peschle, C. Testa, U. (2005) Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with menocytic features of leukemic blasts. Stem Cells, 25, 1862 1871.
31. Riccioni, R., Pasquini, L., Mariani, G., Saulle, E., Rossini, A., Diverio, D., Pelosi, E., Vitale, A., Chierichini, A., Cedrone, M., Foà, R., Lo-Coco, F., Peschle, C. Testa, U. (2005) TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica, 90, 612 624.
32. Saulle, E., Petronelli, A., Pasquini, L., Petrucci, E., Mariani, G., Biffoni, M., Ferretti, G., Scambia, G., Benedetti-Panici, P., Cognetti, F., Humphreys, R., Peschle, C. Testa, U. (2007) Proteasome inhibitors sensitive ovarian cancer cells to TRAIL induced apoptosis. Apoptosis, 12, 635 655.
33. Sayers, T.J., Brooks, A.D., Koh, C.Y., Ma, W., Saki, N., Raziuddin, A., Blazar, B.R., Zhang, X., Elliott, P.J. Murphy, W.J. (2003) The proteasome imhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood, 102, 303 310.
34. Spon, A.C., Lubbert, M., Wierda, W.G. Burger, J.A. (2007) CXCR4 is a prognostic marker in acute myelogenous leukaemia. Blood, 119, 786 791.
35. Stapnes, C., Doskeland, A.P., Hatfield, K., Ersvaer, E., Ryningen, A., Lorens, J.B., Gjertsen, B.T. Bruserud, O. (2007) The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. British Journal of Haematology, 136, 814 828.
36. Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., Lo-Coco, F. Peschle, C. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 100, 2980 2988.
37. Vink, J., Cloos, J. Kaspers, G.J.L. (2006) Proteasome inhibition as novel treatment strategy in leukaemia. British Journal of Haematology, 134, 253 262.